MHRA approves orforglipron weight-loss pill The Medicines and Healthcare products Regulatory Agency said its approval of orforglipron makes the UK the first country in Europe to authorise the medication.…
UK patients being recruited for ribupatide trials Researchers will assess the efficacy of up to 10mg doses of weight-loss drug ribupatide in patients with or without diabetes over around an 18-month period.…
How climate change is reshaping the UK’s risk of vector-borne diseases Recent heatwaves across the UK have brought the issue of climate change to the fore once more. As we work out how to adapt to extreme temperatures, cases of disease transmitted by mosquitoes and ticks are on the rise — but what should we expect and how can pharmacists prepare?…
Common ailments service rated as ‘excellent’ by almost all users, study finds When asked about their experience with the Welsh common ailments service, the majority of survey respondents said that they were able to have their ailment managed at the pharmacy.…
Incretin-based weight-loss drugs should not be deliberately continued in pregnancy, consensus guidelines state The guidelines have been drawn up by a multidisciplinary group of experts following a systematic scoping review.…
How pharmacists can transform prescribing safety in psychiatry Medication errors disproportionately affect patients with mental illness but pharmacists’ expertise in psychopharmacology could help tailor prescribing to better meet individual patient needs.…
Best practice for prescribing drugs with dependence potential An overview of the considerations for prescribing medicines with the risk of dependency, including monitoring, discontinuation and the optimisation of therapeutic outcomes.…
Delivery of 90,000 meningitis B vaccinations for young people prompts call for annual campaign During the first week of the NHS meningococcal B disease vaccination service, more than 8,200 participating pharmacies received around 135,000 bookings.…
Once-weekly HIV pill performs as well as daily treatment in phase III study Researchers found that a once-weekly tablet combining islatravir and lenacapavir performed as well as the once-daily bictegravir–emtricitabine–tenofovir alafenamide regimen.…
NICE recommends heart drug aficamten with simultaneous MHRA approval The National Institute for Health and Care Excellence said that aficamten is likely to be as effective as mavacamten in treating obstructive hypertrophic cardiomyopathy, with “fewer monitoring scans to find the right dose”.…
